Log in Subscribe

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues

Posted
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first quarter profit

Continue reading at ABC - Business wire stories »

Business